Tumor necrosis factor (TNF) is a macrophage/monocyte-derived inflammatory cytokine whose dysregulation has been shown by us and others to play an important role in the pathophysiology of several forms of liver injury including that observed in alcoholic liver disease (ALD). TNF also has been postulated to play a pivotal role in the metabolic complications and wasting of Acquired Immunodeficiency Syndrome (AIDS). There are great similarities between the metabolic abnormalities/complications of AIDS and ALD including anorexia, cachexia, immune suppression, hypoalbuminemia, increased acute phase reactants and edema, to name only a few. We have demonstrated increased plasma TNF, increased monocyte TNF production, and increased hepatic immunohistochemical staining for TNF in patients with ALD. Mitochondrial dysfunction/structural damage is an early event in ALD, and it has also been postulated to play a role in organ dysfunction in AIDS. TNF, per se, causes mitochondrial dysfunction/damage including inhibition of respiration, superoxide generation, and ultimately cell injury. Impairment of normal mitochondrial respiration markedly enhances TNF cytotoxicity. TNF mediated cytotoxicity is thought to be an oxidant injury, and TNF induction of the mitochondrial antioxidant manganous superoxide dismutase (MnSOD) is an endogenous protective mechanism to prevent ongoing TNF cytotoxicity. Regulation of cytokines such as TNF has become a focal point for therapeutic intervention in many diseases including ALD and AIDS. NFkappaB is a transcription factor for several cytokines including TNF and for the HIV virus. NFkappaB is activated by reactive oxygen intermediates, and this activation can be blocked by antioxidants such as vitamin E (Vit E) and glutathione (GSH)-enhancing agents in certain transformed cell lines. It is our working hypothesis that TNF plays an etiologic role in many of the clinical/biochemical abnormalities observed in ALD and AIDS. We postulate that chronic alcohol abuse and HIV infection cause increased gut permeability and endotoxemia, depletion of many nutrient antioxidants (e.g., GSH, Vit E), generation of reactive oxygen intermediates, activation of NFkappaB, increased TNF production, mitochondrial dysfunction with mitochondrial GSH depletion, and ultimately wasting and organ dysfunction including liver injury. The overall research goals of this laboratory are to further define mechanisms and modulatory pathways whereby cytokines, such as TNF, induce metabolic disturbances/liver injury in ALD and in AIDS, with the ultimate goal being development of specific """"""""anticytokine"""""""" therapy for ALD and for AIDS. The specific objectives in this proposal (initially performed in ALD patients) are to: 1) Evaluate dysregulated cytokine (TNF, IL-8) production in ALD, the role of antioxidant status and NFkappaB activation in modulating this cytokine production and the role of """"""""anticytokine"""""""" therapy; 2) Determine the role of mitochondrial dysfunction/protection in alcohol/TNF-mediated hepatotoxicity; and 3) Determine whether unique forms of antioxidant therapy attenuate dysregulated TNF production and mitochondrial dysfunction in patients with ALD. This research spans the spectrum from molecular cellular studies to applied human investigations, with the ultimate goal being improved knowledge and therapy for these two devastating disease processes with overlapping metabolic complications.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Research Project (R01)
Project #
7R01AA010762-06
Application #
6430831
Study Section
Special Emphasis Panel (SRCA (61))
Program Officer
Purohit, Vishnu
Project Start
1996-03-01
Project End
2001-07-31
Budget Start
2001-03-01
Budget End
2001-07-31
Support Year
6
Fiscal Year
2000
Total Cost
$309,600
Indirect Cost
Name
University of Louisville
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Louisville
State
KY
Country
United States
Zip Code
40292
McClain, Craig; Vatsalya, Vatsalya; Cave, Matthew (2017) Role of Zinc in the Development/Progression of Alcoholic Liver Disease. Curr Treat Options Gastroenterol 15:285-295
Zhao, Cuiqing; Liu, Yanlong; Xiao, Jian et al. (2015) FGF21 mediates alcohol-induced adipose tissue lipolysis by activation of systemic release of catecholamine in mice. J Lipid Res 56:1481-91
Smart, Laura; Gobejishvili, Leila; Crittenden, Neil et al. (2013) Alcoholic Hepatitis: Steroids vs. Pentoxifylline. Curr Hepat Rep 12:59-65
Jackson, Sara L; Cook, Andrea J; Miglioretti, Diana L et al. (2012) Are radiologists' goals for mammography accuracy consistent with published recommendations? Acad Radiol 19:289-95
Kirpich, Irina A; Feng, Wenke; Wang, Yuhua et al. (2012) The type of dietary fat modulates intestinal tight junction integrity, gut permeability, and hepatic toll-like receptor expression in a mouse model of alcoholic liver disease. Alcohol Clin Exp Res 36:835-46
Gobejishvili, Leila; Avila, Diana V; Barker, David F et al. (2011) S-adenosylmethionine decreases lipopolysaccharide-induced phosphodiesterase 4B2 and attenuates tumor necrosis factor expression via cAMP/protein kinase A pathway. J Pharmacol Exp Ther 337:433-43
Heilman, Jacqueline M; Burke, Tom J; McClain, Craig J et al. (2011) Transactivation of gene expression by NF-?B is dependent on thioredoxin reductase activity. Free Radic Biol Med 51:1533-42
Zhao, Yantao; Zhong, Wei; Sun, Xiuhua et al. (2011) Zinc deprivation mediates alcohol-induced hepatocyte IL-8 analog expression in rodents via an epigenetic mechanism. Am J Pathol 179:693-702
Ghare, Smita; Patil, Madhuvanti; Hote, Prachi et al. (2011) Ethanol inhibits lipid raft-mediated TCR signaling and IL-2 expression: potential mechanism of alcohol-induced immune suppression. Alcohol Clin Exp Res 35:1435-44
Beier, Juliane I; McClain, Craig J (2010) Mechanisms and cell signaling in alcoholic liver disease. Biol Chem 391:1249-64

Showing the most recent 10 out of 21 publications